Johnson & Johnson at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Good morning. I'm Louise Chen, the large-cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Johnson & Johnson. Johnson & Johnson is a leading global health care company with a diversified business model that includes Pharmaceuticals, Medical Devices and Consumer. The company's Pharmaceutical business has been a top performer in the industry. 2021 could be in Johnson & Johnson's 10th consecutive year of above-market growth. Therefore, we are thrilled to have with us today, Mathai Mammen, Global Head of R&D for the Janssen Pharmaceutical Companies of Johnson & Johnson; and Scott White, company group Chairman of North America Pharmaceuticals, to discuss the potential of Johnson & Johnson's commercial products and pipeline of its first-in-class and best-in-class drugs.
So before we start the Q&A, Mathai and Scott, would you like to make any opening remarks?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |